⌘K

Login Start Free

Home/Filings/4/0000943819-25-000095

4//SEC Filing

Farrell Michael J. 4

Accession 0000943819-25-000095

CIK 0000943819other

View on SEC.gov Company Profile

Filed

Nov 9, 7:00 PM ET

Accepted

Nov 10, 7:07 PM ET

Size

13.2 KB

Accession

0000943819-25-000095

Insider Transaction Report

Form 4

Period: 2025-11-07

Farrell Michael J.

DirectorChairman and CEO

Transactions

Sale
ResMed Common Stock
2025-11-07$249.75/sh−8,011$2,000,773→ 467,866 total
Exercise/Conversion
ResMed Common Stock Options
2025-11-07−983→ 7,028 total
Exercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (983 underlying)
Exercise/Conversion
ResMed Common Stock
2025-11-07$101.64/sh+7,028$714,326→ 475,877 total
Exercise/Conversion
ResMed Common Stock
2025-11-07$101.64/sh+983$99,912→ 468,849 total
Exercise/Conversion
ResMed Common Stock Options
2025-11-07−7,028→ 0 total
Exercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (7,028 underlying)

Holdings

ResMed Common Stock
(indirect: By Trust)
2,090

Footnotes (4)

[F1]The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
[F2]Includes 74.3412 shares of ResMed stock purchased on October 31, 2025, through the ResMed Employee Stock Purchase Plan.
[F3]This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price.
[F4]Represents date options first become exercisable. Options vest 1/3 per year.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

RESMED INC

CIK 0000943819

Entity typeother

Related Parties

1

filerCIK 0001485164

Filing Metadata

Form type: 4
Filed: Nov 9, 7:00 PM ET
Accepted: Nov 10, 7:07 PM ET
Size: 13.2 KB

View on SEC.gov